The stock of Incyte Corporation (NASDAQ:INCY) is a huge mover today! About 878,968 shares traded hands. Incyte Corporation (NASDAQ:INCY) has risen 13.32% since April 4, 2016 and is uptrending. It has outperformed by 12.23% the S&P500.
The move comes after 5 months positive chart setup for the $16.44B company. It was reported on Nov, 4 by Barchart.com. We have $114.56 PT which if reached, will make NASDAQ:INCY worth $5.10 billion more.
Incyte Corporation (NASDAQ:INCY) Ratings Coverage
Out of 19 analysts covering Incyte (NASDAQ:INCY), 17 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 89% are positive. Incyte has been the topic of 39 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The company was initiated on Wednesday, July 13 by RBC Capital Markets. JMP Securities maintained the shares of INCY in a report on Monday, October 10 with “Market Outperform” rating. On Tuesday, August 18 the stock rating was maintained by Piper Jaffray with “Overweight”. The company was initiated on Wednesday, November 18 by Goldman Sachs. The stock of Incyte Corporation (NASDAQ:INCY) has “Overweight” rating given on Friday, February 12 by Barclays Capital. Nomura maintained the shares of INCY in a report on Tuesday, October 6 with “Buy” rating. The company was maintained on Wednesday, October 12 by RBC Capital Markets. On Tuesday, August 18 the stock rating was downgraded by Vetr to “Buy”. As per Wednesday, August 5, the company rating was maintained by UBS. UBS maintained the stock with “Buy” rating in Wednesday, November 4 report.
According to Zacks Investment Research, “Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of new small molecule drugs for cancer and inflammation. Incyte also has strategic alliances with Lexicon Genetics and Medarex focused on the discovery and development of protein therapeutics or antibodies to treat inflammatory diseases and cancer.”
Insitutional Activity: The institutional sentiment increased to 1.19 in 2016 Q2. Its up 0.26, from 0.93 in 2016Q1. The ratio is positive, as 32 funds sold all Incyte Corporation shares owned while 116 reduced positions. 45 funds bought stakes while 131 increased positions. They now own 172.01 million shares or 5.11% less from 181.27 million shares in 2016Q1.
Moreover, State Bank Of America De has 0.01% invested in Incyte Corporation (NASDAQ:INCY) for 594,933 shares. Geode Capital Lc accumulated 0.05% or 1.12M shares. Blackrock Gp Limited has 1.05M shares for 0.04% of their US portfolio. Financial Bank Of New York Mellon Corp accumulated 0.02% or 724,332 shares. Northern Tru Corp has 886,492 shares for 0.02% of their US portfolio. Peak6 Invs Lp, a Illinois-based fund reported 2,741 shares. Dekabank Deutsche Girozentrale, a Germany-based fund reported 208,114 shares. Goldman Sachs Group Inc has 0.02% invested in the company for 833,608 shares. Gulf Intl Fincl Bank (Uk) last reported 50,575 shares in the company. Nomura Asset holds 0.07% of its portfolio in Incyte Corporation (NASDAQ:INCY) for 44,822 shares. Principal Fincl Inc accumulated 34,495 shares or 0% of the stock. Macquarie Gru Limited accumulated 50,610 shares or 0.01% of the stock. The California-based Capital Ca has invested 1.1% in Incyte Corporation (NASDAQ:INCY). The Washington-based Rainier Inv Mgmt Ltd Liability has invested 0.21% in Incyte Corporation (NASDAQ:INCY). Winslow Evans & Crocker holds 0% of its portfolio in Incyte Corporation (NASDAQ:INCY) for 1,200 shares.
Insider Transactions: Since July 29, 2016, the stock had 0 insider purchases, and 6 insider sales for $12.46 million net activity. Huber Reid M sold 10,000 shares worth $879,600. Shares for $2.35M were sold by Flannelly Barry P. SWAIN PAULA J also sold $900,000 worth of Incyte Corporation (NASDAQ:INCY) on Thursday, October 20.
Another recent and important Incyte Corporation (NASDAQ:INCY) news was published by Businesswire.com which published an article titled: “More Than 20 Abstracts Highlighting Data from Incyte’s Portfolio Accepted for …” on November 03, 2016.
INCY Company Profile
Incyte Corporation, incorporated on April 8, 1991, is a biopharmaceutical company. The Firm is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Firm focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The Company’s pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Firm has discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the compound in its JAK program, which is an oral JAK1 and JAK2 inhibitor. JAKAFI orphan drug is indicated for Myelofibrosis (MF), Polycythemia Vera (PV) and essential thrombocythemia.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.